Clinical Trials on Human Influenza

Total 8052 results

Novartis
Novartis Vaccines

Completed

Safety, Tolerability and Immunogenicity of Two Doses of Adjuvanted Monovalent Influenza Vaccine Administered to Healthy Adult and Elderly Subjects

Pandemic Influenza Disease

Finland, Germany
China Academy of Chinese Medical Sciences
Renmin Hospital of Wuhan University; Children's Hospital of Soochow University and other collaborators

Unknown

Clinical Study of Reduning Injection for the Treatment of Influenza in Children

Influenza in Children
Public Health England

Completed

Assessment of Viral Shedding in Children Previously in Receipt of Multiple Doses of Live Attenuated Influenza Vaccine (LAIV) Compared to Influenza Vaccine-naïve Controls (Flushed)

Influenza | Vaccination | Influenza Vaccination

United Kingdom
Vaxart

Completed

Assessment of an Oral Influenza B Vaccine Tablet (VXA-BYW.10) Following Single Dose Administration in Healthy Adults

Seasonal Influenza B

New Zealand
University Health Network, Toronto

Completed

Adjuvanted Influenza Vaccine in Stem Cell Transplant

Transplantation | Influenza Vaccines
Novartis Vaccines

Completed

Immunogenicity, Tolerability and Safety of One or Two Doses of an Adjuvanted Swine-origin A H1N1 Influenza Vaccine in Healthy Subjects 18 or More Years of Age Both Vaccinated and Not Yet Vaccinated Against Seasonal Influenza 2009/10

Pandemic Influenza Disease

Italy
David Scheifele
Canadian Institutes of Health Research (CIHR); PHAC/CIHR Influenza Research...

Completed

Rapid Evaluation of Pandemic H1N1 Influenza Vaccine in Aboriginal Children and Adults

H1N1/2009 Influenza

Canada
Novartis Vaccines

Completed

Safety and Immunogenicity of Trivalent Subunit Influenza Vaccine Produced in Mammalian Cell Culture Using the Strain Composition 2007/2008

Seasonal Influenza Vaccine

Germany
University of Nottingham

Completed

Virus Shedding and Environmental Deposition of a Novel Influenza Virus

Novel (H1N1) Influenza

United Kingdom
University of Manitoba
Hoffmann-La Roche

Terminated

Trial Comparing High Versus Standard Dose Oseltamivir in Severe Influenza Infection in ICU (ROSII)

Influenza A Virus

Canada
Taipei Medical University WanFang Hospital

Unknown

Analysis of the Results From Influenza Rapid Test A Positive and H1N1 Real Time RT-PCR

H1N1 Influenza Virus

Taiwan
Seattle Children's Hospital
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Inactivated Influenza Virus Vaccine Among Healthy Children 6-12 Weeks of Age (GRC28)

Inactivated Influenza Vaccine

United States
Novartis
Novartis Vaccines

Completed

Safety and Immunogenicity of Trivalent Split Influenza Vaccine Using the Strain Composition 2007/2008

Seasonal Influenza | Vaccine

Germany
Sinovac Biotech Co., Ltd
Centers for Disease Control and Prevention, China

Completed

Safety and Immunogenicity of an Inactivated Pandemic Influenza Vaccine

Prevention | Pandemic Influenza
Novartis
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two(Surface Antigen Adjuvanted With MF59C.1) Influenza Vaccines in Non-Elderly Adult and Elderly Subjects

Pandemic Influenza Disease

Italy
Evidation Health
Biomedical Advanced Research and Development Authority

Enrolling by invitation

Predict + Protect Study: Exploring the Effectiveness of a Predictive Health Education Intervention on the Adoption of Protective Behaviors Related to ILI

COVID-19 | Influenza | Influenza A | Respiratory Syncytial Virus (RSV) | Influenza B

United States
Janssen Research & Development, LLC

No longer available

Pre-Approval Access to Pimodivir for the Treatment of Patients With H7N9 Influenza A Infection

H7N9 Subtype of Influenza A Virus
Finnish Institute for Health and Welfare

Completed

Evaluation of Pandemic Vaccination Campaign

Influenza Caused by the Novel A(H1N1)v Influenza Virus

Finland
Sanofi Pasteur, a Sanofi Company

Completed

Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2020-2021 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively

Healthy Volunteers | Influenza Immunization

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older

Healthy Volunteers | Influenza Immunization

Japan
Celltrion

Terminated

A Study to Evaluate the Efficacy and Safety of CT-P27 in Acute Uncomplicated Influenza A Infection

Influenza A

Korea, Republic of
National Institute of Allergy and Infectious Diseases...

Completed

Immunogenicity and Safety Study of Inactivated Subunit H5N1 Influenza Vaccine in Prior Recipients of Live Attenuated H2N2, H6N1 and H9N2 Influenza Vaccines and in H5N1 and Live Attenuated Vaccine Naïve Individuals

Influenza

United States
Fundacio d'Investigacio en Atencio Primaria Jordi...

Completed

Effectiveness of a Brief Intervention for Acceptance of Influenza Vaccine in the Primary Care Setting

Health Education | Influenza Vaccination

Spain
National Institute of Allergy and Infectious Diseases...

Completed

Blood and Plasma Collection For Use in Future Clinical Trials

Influenza A Virus Infection

United States
Genentech, Inc.

Completed

A Study of MHAA4549A as Monotherapy for Acute Uncomplicated Seasonal Influenza A in Otherwise Healthy Adults

Influenza A

United States, Spain, Korea, Republic of, United Kingdom, Canada, New Zealand, South Africa
Public Health England
Institute of Child Health

Completed

A Phase III/IV Open-label Study of the Immunogenicity and Safety of a Single Dose of a Live Attenuated Influenza Vaccine (LAIV) (FluenzTM) for Each of Three Successive Years in Children naïve to, or in Previous Receipt of the AS03B Adjuvanted H1N1 (2009) Influenza Vaccine (Pandemrix ™). (LAIV Immuno)

Live Attenuated Influenza Vaccine

United Kingdom
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Adjuvanted and One Non-adjuvanted H5N1 Influenza Vaccine in Adults

Influenza

Italy
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects Using Four Different Vaccination Schedules

Pre-pandemic Influenza Vaccine

Czech Republic
Beijing Chaoyang District Centre for Disease Control...

Unknown

Safety and Immunogenicity Study of Quadrivalent Influenza Virus Vaccine in Healthy People Aged Years 3-60

Quadrivalent Influenza Virus Vaccine
University of Rochester
National Institutes of Health (NIH)

Completed

Effects of Age on Response to the 2009 H1N1 Virus Vaccine

2009 H1N1 Influenza Virus

United States
University of British Columbia

Completed

Enhancing Influenza Vaccination in Seniors With TLR (Toll Like Receptor) Agonists

Influenza Vaccination in Seniors

Canada
National Institute of Allergy and Infectious Diseases...

Completed

H5N1 Priming and Boosting Strategies

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

Cell-Mediated Immune Responses to Influenza A/H5N1 Vaccine

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

H5N1 Vaccine Intramuscular Versus Intradermal in Healthy Adults

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

H5N1 Mix and Match With MF59

Influenza

United States
Centers for Disease Control and Prevention

Unknown

Inactivated Influenza A/H5N1 Vaccine in Adult Subjects at Risk of Occupational Exposure to Live H5N1 Viruses

Influenza

United States
Fluart Innovative Vaccine Ltd, Hungary

Completed

Tolerability and Immunogenicity Study of FLUVAL P H1N1 Flu Vaccine of Omninvest in Children and Adolescents

Influenza, Human | Novel 2009 Influenza H1N1

Hungary
National Institute of Allergy and Infectious Diseases...

Completed

A/H5N1 Vaccine in Healthy Children Aged 2-9 Years

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

Dose-Escalating Trial Using Vero Cell-culture Derived H5N1 +/- Aluminum in Adults

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

Phase I Open-Label Study of Recombinant DNA Plasmid Vaccine, VRC-AVIDNA036-00-VP, Encoding for Influenza Virus H5 Hemagglutinin Protein Given Intradermally

Influenza A Virus, H5N1 Subtype | Influenza A Virus | Influenzavirus A | H5N1 Virus | Orthomyxovirdae

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety Study of Avian Flu Vaccine

Influenza A Virus, H5N1 Subtype | Influenza A Virus | Influenzavirus A | Orthomyxoviridae | H5N1 Virus

United States
Sanofi

Completed

Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2023/24

Influenza Immunization (Healthy Volunteers)

Finland, Germany
Guangdong Raynovent Biotech Co., Ltd

Completed

A Study of ZSP1273 Tablets in Patients With Acute Uncomplicated Influenza A

Influenza A

China
Seqirus
Novartis Vaccines

Completed

Dose Ranging Study to Evaluate Immunogenicity and Safety of Adjuvanted or Non-adjuvanted Cell Culture-derived H5N1 Influenza Vaccine in Young Adults (18-40 Years Old)

Influenza

United States, Germany
Guangdong Raynovent Biotech Co., Ltd

Completed

Study of ZSP1273 in Patients With Acute Uncomplicated Influenza A

Influenza A

China
National Institute of Allergy and Infectious Diseases...

Completed

H7 Influenza Prime-Boost Regimens in Healthy Adults: Recombinant H7 DNA Plasmid Vaccine, VRC-FLUDNA071-00-VP, Administered Alone or With Monovalent Influenza Subunit Virion H7N9 Vaccine (MIV) as Prime With MIV Boost Compared to MIV Prime With MIV Boo...

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

H5N1 Vaccination With and Without AS03: Systems Biology Analysis

Influenza

United States
University of Colorado, Denver
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Centralized IIS-based Reminder/Recall to Increase Childhood Influenza Vaccination Rates

Reminder Systems | Influenza Vaccines
National Institute of Allergy and Infectious Diseases...

Completed

H7N9 Boost in Healthy Adults

Influenza

United States
GlaxoSmithKline

Completed

A Trial to Test the Response to Different Vaccination Regimens With an H5N1 Vaccine With AS03 in Adults Aged 18-64

Influenza

Canada

3

Subscribe